• Gold Glyconanoparticles Combined with 91–99 Peptide of the Bacterial Toxin, Listeriolysin O, Are Efficient Immunotherapies in Experimental Bladder Tumors 

      Terán-Navarro, Hector; Zeoli, Andrea; Salines-Cuevas, David; Marradi, Marco; Montoya, Noemí ; Gonzalez-Lopez, Elena; Ocejo-Vinyals, J. Gonzalo; Dominguez-Esteban, Mario; Gutierrez-Baños, Jose Luis; Campos-Juanatey, Felix; Yañez-Diaz, Sonsoles; Garcia-Castaño, Almudena; Rivera, Fernando; Duran, Ignacio; Álvarez-Domínguez, Carmen (Cancers, 2022)
      This study presents proof of concept assays to validate gold nanoparticles loaded with the bacterial peptide 91–99 of the listeriolysin O toxin (GNP-LLO91–99 nanovaccines) as immunotherapy for bladder tumors. GNP-LLO91–99 ...
    • Insect Venom Immunotherapy: Analysis of the Safety and Tolerance of 3 Buildup Protocols Frequently Used in Spain 

      Gutiérrez Fernández, D; Moreno-Ancillo, A; Fernández Meléndez, S; Domínguez-Noche, C; Gálvez Ruiz, Pablo ; Alfaya Arias, T (Journal of Investigational Allergology and Clinical Immunology, 2016)
      Introduction: Hymenoptera venom immunotherapy (VIT) is an effective treatment but not one devoid of risk, as both local and systemic adverse reactions may occur, especially in the initial phases. We compared the tolerance ...
    • The Importance of Understanding the Stages of COVID-19 in Treatment and Trials 

      Griffin, Daniel O.; Brennan-Rieder, Denise; Ngo, Binh; Kory, Pierre; Confalonieri, Marco; Shapiro, Leland; Iglesias, Jose; Dube, Michael; Nanda, Neha; In, Gino K.; Arkfeld, Daniel; Chaudhary, Preet; Campese, Vito M.; Hanna, Diana L.; Sawcer, David; Ehresmann, Glenn; Peng, David; Smorgorzewski, Miroslaw; Amstrong, April; Vinjevoll, Eivind H.; Dasgupta, Rajkumar; Sattler, Fred R.; Mussini, Cristina; Mitjà, Oriol; Soriano, Vicente ; Peschanski, Nicolas; Hayem, Gilles; Piccirillo, Maria Carmela; Lobo-Ferreira, António; B. Rivero, Iraldo; Hung, Ivan F. H.; Rendell, Marc; Ditmore, Stephen; Varon, Joseph; Marik, Paul (AIDS reviews, 2021)
      COVID-19, caused by SARS-CoV-2, continues to be a major health problem since its first description in Wuhan, China, in December 2019. Multiple drugs have been tried to date in the treatment of COVID-19. Critical to treatment ...